Johns Hopkins and local biotech team up for new manufacturing site; New oral drug platform to help accelerate R&D timeline
Johns Hopkins University and a Maryland-based biotech will join forces to develop a cell and gene therapy processing facility at the university, set to open in 2023.
Orgenesis will join forces on the POCare Center, also known as the Maryland Center for Cell Therapy Manufacturing, in part thanks to a $5 million grant from the state. The facility will be 7,000 square feet, and help clinicians and researchers at Johns Hopkins with a more streamlined path from the lab to patient trials. This allows for more in-house manufacturing, and less outsourcing to third parties.
Right now, Orgenesis is using lab space at FastForward, Johns Hopkins Technology Ventures’ Innovation Hub. The company will send 30 of its employees at the site next year upon completion.
In a statement, CEO Vered Caplan said:
Orgenesis continues to develop and extend key partnerships within its international POCare Network. These international partnerships are now experiencing significant investment and construction across the globe to build on the achievements within the Network, as illustrated by our expanded collaboration with Johns Hopkins. We are honored to work with Johns Hopkins, America’s first research university and home to nine world-class academic divisions working together in one university. The POC Center at Johns Hopkins will help propel the development of therapies targeting a range of conditions that directly affect the lives of millions of patients.
Construction will start next quarter and should be completed by Q2 2023.
New oral drug platform to help accelerate R&D timeline
Catalent is launching its new Xpress Pharmaceuticals service to accelerate the development of oral drugs through Phase I clinical studies. The approach uses on-demand clinical manufacturing, clinical testing and regulatory support to reduce the cost and time taken to complete in-human trials.
The service allows Catalent to work alongside innovator and clinical research organizations, and provide material with the necessary data to prepare for dosing patients at a clinical site. The service will be carried out at Catalent’s Nottingham, UK, and Beinheim, France, sites.
“Achieving early clinical success milestones as fast as possible is crucial in modern drug development, especially for emerging innovators, and this new service combines Catalent’s core expertise in drug formulation with manufacturing, analytics, and regulatory expertise, to design better drugs for use in adaptive trials,” said Jonathan Arnold, the president of oral and specialty delivery.
Editor’s Note: For more news and exclusive coverage from the manufacturing beat, subscribe to the Endpoints Manufacturing weekly report in your reader profile.